Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Clinical trial NCT00439725 · COMPLETED

Trial details

NCT number: NCT00439725
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Venous Thromboembolism

Start date: 2007-02-01
Primary completion: 2009-08-01
Enrollment: 1197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.